12/9
10:18 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/9
07:09 am
kura
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting [Yahoo! Finance]
Medium
Report
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting [Yahoo! Finance]
12/9
07:00 am
kura
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Low
Report
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
12/2
07:44 am
kura
Kura Oncology to Host Virtual Investor Event on December 9, 2024 [Yahoo! Finance]
Low
Report
Kura Oncology to Host Virtual Investor Event on December 9, 2024 [Yahoo! Finance]
12/2
07:30 am
kura
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Low
Report
Kura Oncology to Host Virtual Investor Event on December 9, 2024
11/25
07:40 am
kura
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
Low
Report
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
11/25
07:30 am
kura
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Low
Report
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
11/22
08:12 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Bank of America Co. from $36.00 to $29.00. They now have a "buy" rating on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Bank of America Co. from $36.00 to $29.00. They now have a "buy" rating on the stock.
11/21
11:34 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.
11/21
10:45 am
kura
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]
Low
Report
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]
11/21
09:45 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
11/21
09:00 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/21
08:05 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a "buy" rating on the stock.
High
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a "buy" rating on the stock.
11/20
05:02 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias [Yahoo! Finance]
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias [Yahoo! Finance]
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
03:14 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/19
12:46 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
11/13
01:08 pm
kura
Syndax's stock sinks by 25% despite AML trial meeting primary endpoint [Yahoo! Finance]
Low
Report
Syndax's stock sinks by 25% despite AML trial meeting primary endpoint [Yahoo! Finance]
11/13
08:06 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
11/13
12:08 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/8
04:12 pm
kura
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses [Yahoo! Finance]
Low
Report
Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses [Yahoo! Finance]
11/7
04:05 pm
kura
Kura Oncology Reports Third Quarter 2024 Financial Results
Medium
Report
Kura Oncology Reports Third Quarter 2024 Financial Results